Evidence check: CYP2D6 in the context of Darmgesundheit

CYP2D6 is a liver enzyme primarily involved in drug metabolism. A direct role in gut health (microbiome composition, intestinal barrier) is not supported by current evidence. CYP2D6 expression in the gut is negligible; any effects on gut function are indirect and drug-specific (e.g., opioids affecting motility). No robust human studies link CYP2D6 variants to gut health outcomes. DNA tests for CYP2D6 are designed for pharmacogenetic guidance, not for assessing gut flora or leaky gut. MyBody-X does not offer microbiome testing; using a CYP2D6 result to infer gut health status is not evidence-based. Evidence: unclear/mechanistic. Caveat: Do not use CYP2D6 genotype to make dietary or probiotic decisions for gut health.